Serotonin–norepinephrine–dopamine reuptake inhibitor

Serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of psychiatric medication that simultaneously inhibits the reuptake of the three monoamine neurotransmitters: serotonin, norepinephrine, and dopamine. It is used in the treatment of some psychiatric disorders. SNDRI drugs are considered potential therapeutic agents in treating depression, anxiety disorders, and possibly other conditions.

Mechanism of Action

SNDRI medications work by inhibiting the reuptake of serotonin, norepinephrine, and dopamine, which are neurotransmitters involved in mood regulation and other cognitive functions. By blocking the reuptake of these neurotransmitters, SNDRI drugs increase their availability in the synaptic cleft, enhancing neurotransmission and improving mood and cognitive functions.

Clinical Uses

SNDRI drugs are primarily researched for their potential in treating major depressive disorder (MDD), anxiety disorders, and certain other psychiatric conditions. Their unique mechanism of action, affecting three key neurotransmitters, may offer advantages over other antidepressants that target only one or two of these chemicals.

Side Effects

The side effects of SNDRI medications can vary but may include nausea, dizziness, insomnia, and increased blood pressure. Due to their action on multiple neurotransmitters, they may also have a higher risk of causing serotonin syndrome, a potentially life-threatening condition.

Examples

As of the current knowledge, few drugs are classified strictly as SNDRI, with most research in this area still being experimental. One example of an SNDRI is nomifensine, which was used as an antidepressant but was withdrawn from the market due to adverse effects.

Comparison with Other Antidepressants

SNDRI drugs differ from Selective serotonin reuptake inhibitors (SSRIs) and Serotonin–norepinephrine reuptake inhibitors (SNRIs) by their additional action on dopamine reuptake. This broader mechanism of action may provide benefits in treating certain patient populations, though it also comes with a potentially increased risk of side effects and interactions.

Future Directions

Research into SNDRI drugs continues, with the aim of finding effective treatments with fewer side effects. The development of new SNDRI compounds and the investigation into their clinical uses are areas of ongoing study in the field of psychopharmacology.

See Also

• Antidepressant
• Monoamine neurotransmitter
• Psychopharmacology
• Dopamine
• Norepinephrine
• Serotonin

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Serotonin–norepinephrine–dopamine reuptake inhibitor gallery

• 

  3,4-Diphenylpiperidines

• 

  MDL 47,832

• 

  3,4-Diphenylquinuclidine